CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
22.37
+0.85 (3.95%)
At close: Apr 25, 2025, 4:00 PM
28.48
+6.11 (27.31%)
After-hours: Apr 25, 2025, 7:34 PM EDT
CG Oncology Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for CG Oncology stock have an average target of 65.11, with a low estimate of 50 and a high estimate of 75. The average target predicts an increase of 191.06% from the current stock price of 22.37.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 7 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +235.27% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +235.27% | Mar 25, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $55 | Buy | Initiates | $55 | +145.86% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +235.27% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +235.27% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
759.49K
from 1.14M
Decreased by -33.32%
Revenue Next Year
124.08M
from 759.49K
Increased by 16,237.24%
EPS This Year
-1.84
from -1.41
EPS Next Year
-1.58
from -1.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.5M | 241.5M | 347.6M | ||
| Avg | 759,492 | 124.1M | 240.1M | ||
| Low | n/a | 49.0M | 104.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 121.2% | 31,702.8% | 180.1% | ||
| Avg | -33.3% | 16,237.2% | 93.5% | ||
| Low | - | 6,351.7% | -15.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.05 | -0.11 | 0.87 |
| Avg | -1.84 | -1.58 | -0.33 |
| Low | -2.39 | -3.49 | -1.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.